Kymanox Acquires Agilis Consulting Group, Marking Second Acquisition This Year
By Alex Keown
March 24, 2023
Life sciences professional services company Kymanox Corporation acquired Agilis Consulting Group, expanding the company’s specialized service capabilities for clients.
Morrisville, N.C.-based Kymanox said integrating Agilis, a professional services company, extends its human factors capabilities through the addition of talent that provides “unparalleled regulatory strategy and support.” The acquisition of Ohio-based Kymanox enables both company to realize the shared goal of bringing new medicines to patients, while bolstering service capabilities through a broad array of specialized service offerings.
Kymanox offers its clients expertise in multiple areas, including offering engineering, scientific, project management, quality assurance, human factors, testing and quality control, regulatory support, and more. Evan Edwards, chief innovation officer at Kymanox said the addition of Agilis boots the company’s human factor capabilities that benefit client programs from start through regulatory submissions and commercialization. Edwards noted a strong familiarity with the Agilis team and the similar values that company shares with Agilis, particularly the “right-first-time” standard. The combination of teams will ensure successful FDA, EMA, and other regulatory submissions for clients.
“The strength of the combined companies’ service offerings and expertise will benefit customers who bring important biologics, including biosimilars and cell and gene therapies (C>s), pharmaceuticals, drug/device combinations products, and medical devices, to markets worldwide,” Kymanox said in its announcement.
Agilis offers early-stage design evaluation and product concept consultation on a wide range of products across a variety of therapeutic areas in order to improve use-related safety, effectiveness, and overall usability. Their proprietary human-factors engineering strategies seek to cost-effectively optimize device design in a way that aligns with regulatory requirements.
“For more than 20 years, Agilis Consulting Group has distinguished itself in its ability to provide ‘first time’ regulatory success in medical human factors delivered with integrity, agility, and professionalism,” stated Pat Patterson, Founder and CEO of Agilis. “As our growing team and highly valued global clients began seeking more opportunities and more services delivered to the same high standards, it became clear that Kymanox would be the ideal partner. Combined with Kymanox’s diverse team of experts and broader service offerings, the synergy of our two companies will meet the demands of the rapidly growing medical device, pharmaceutical, and biologics industries.”
Full terms of the acquisition were not disclosed in the announcement.
For Kymanox, the acquisition of Agilis comes weeks after the company expanded its European client service capabilities with the acquisition of anteris medical GmbH and anteris helvetia AG. The combination of the capabilities of the two anteris’ companies provide Kymanox with an expanded footprint in Europe, one in Germany and another in Switzerland. In a previous interview with BioBuzz, Kymanox Chief Revenue Officer, Matt Neighoff, said the synergies from the merger with anteris provide greater expertise in areas like European regulatory affairs, strategy, and pathways, as well as with biosimilar development and commercialization.
- About the Author
- Latest Posts
Alex Keown is a freelance journalist who writes about a variety of subjects including the pharma, biotech, and life science industries. Prior to freelancing, Alex has served as a staff writer and editor for several publications.
